Scarica l'app Stockscreener
30.40
0.67%
-0.49
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Precedente Chiudi:
$30.89
Aprire:
$30.92
Volume 24 ore:
394.66K
Relative Volume:
0.17
Capitalizzazione di mercato:
$3.54B
Reddito:
-
Utile/perdita netta:
$-472.34M
Rapporto P/E:
-7.3325
EPS:
-4.1459
Flusso di cassa netto:
$-340.33M
1 W Prestazione:
+8.04%
1M Prestazione:
-6.31%
6M Prestazione:
-15.41%
1 anno Prestazione:
+13.72%
Intervallo 1D:
$30.27
$31.00
Intervallo di 1 settimana:
$28.61
$31.00
Portata 52W:
$22.96
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Nome
Viking Therapeutics Inc
Settore
Industria
Telefono
858-704-4660
Indirizzo
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
30.50 | 3.59B | 0 | -472.34M | -340.33M | -4.1459 |
VRTX
Vertex Pharmaceuticals Inc
|
436.50 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
639.76 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
801.80 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.70 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
152.54 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-26 | Iniziato | Wolfe Research | Peer Perform |
| 2025-10-29 | Iniziato | Canaccord Genuity | Buy |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Iniziato | Goldman | Neutral |
| 2025-02-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-07 | Iniziato | Citigroup | Neutral |
| 2024-12-02 | Iniziato | Piper Sandler | Overweight |
| 2024-11-22 | Iniziato | B. Riley Securities | Buy |
| 2024-11-04 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-11 | Iniziato | JP Morgan | Overweight |
| 2024-06-27 | Iniziato | Morgan Stanley | Overweight |
| 2024-05-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Reiterato | Oppenheimer | Outperform |
| 2024-03-07 | Iniziato | Jefferies | Buy |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2023-05-31 | Ripresa | ROTH MKM | Buy |
| 2023-03-28 | Reiterato | Maxim Group | Buy |
| 2023-03-17 | Iniziato | Stifel | Buy |
| 2021-07-29 | Ripresa | BTIG Research | Buy |
| 2021-05-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Iniziato | BMO Capital Markets | Outperform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-05-01 | Iniziato | BTIG Research | Buy |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-25 | Iniziato | Stifel | Buy |
| 2019-03-29 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Reiterato | Maxim Group | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-12 | Iniziato | B. Riley FBR | Buy |
| 2018-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-18 | Reiterato | Maxim Group | Buy |
| 2018-09-18 | Reiterato | Raymond James | Outperform |
| 2018-07-20 | Iniziato | SunTrust | Buy |
| 2018-06-28 | Iniziato | Raymond James | Outperform |
| 2018-06-01 | Reiterato | Laidlaw | Buy |
| 2018-05-31 | Reiterato | Maxim Group | Buy |
| 2018-03-26 | Ripresa | H.C. Wainwright | Buy |
| 2017-11-28 | Reiterato | Maxim Group | Buy |
| 2017-11-21 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
Prediction: These 2 Obesity Drug Stocks Could Double in 2026 - AOL.com
Is Viking Therapeutics (VKTX) Pricing In Too Much Optimism After Recent Share Price Swings? - simplywall.st
Prediction: These 2 Obesity Drug Stocks Could Double in 2026 - The Motley Fool
Don't buy Viking Therapeutics stock until you read this - MSN
Don't Buy Viking Therapeutics Stock Until You Read This - AOL.com
Could Viking Therapeutics Be the Next Eli Lilly? - AOL.com
A Look At Viking Therapeutics (VKTX) Valuation As Shares Show Mixed Recent Returns - Yahoo Finance
Is Viking Therapeutics a Top Takeover Target? - The Motley Fool
Should New Phase 2 Oral VK2735 Weight-Loss Data Require Action From Viking Therapeutics (VKTX) Investors? - simplywall.st
Viking Therapeutics, Inc. Stock 12‑Month Price Target Raised to $95.4, Implies 209% Upside - TradingView
Viking Therapeutics Analyst Ratings and Price Targets | NASDAQ:VKTX - Benzinga
2 Stocks That Could Realistically Double by 2030 - The Motley Fool
VKTX Technical Analysis | Trend, Signals & Chart Patterns | VIKING THERAPEUTICS INC (NASDAQ:VKTX) - ChartMill
Viking Therapeutics faces timeline risk, but upside could be huge - MSN
Viking Therapeutics to Participate at Upcoming Investor Conferences - StreetInsider
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party - The Globe and Mail
Three Biotechs That Are Top Takeover Targets - 24/7 Wall St.
Viking Therapeutics, Inc.Common Stock (NQ: VKTX - The Chronicle-Journal
VKTX stock slips premarket: A surprise weight loss drug beats Novo Nordisk in early animal tests - MSN
Viking Therapeutics, Inc. (VKTX) declines more than market: Some information for investors - MSN
The Bull Case For Viking Therapeutics (VKTX) Could Change Following New Oral VK2735 Obesity Data Release - Yahoo Finance
Avoiding Lag: Real-Time Signals in (VKTX) Movement - Stock Traders Daily
symbol__ Stock Quote Price and Forecast - CNN
How New Oral VK2735 Obesity Data At Viking Therapeutics (VKTX) Has Changed Its Investment Story - simplywall.st
VKTX Q1 earnings miss on higher phase 3 development costs - MSN
Viking Therapeutics (VKTX) Valuation Revisited After New VK2735 Phase 2 Obesity Data Spurs Investor Interest - simplywall.st
Viking Therapeutics (VKTX) Reveals Promising Phase 2 Trial Resul - GuruFocus
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTU - GuruFocus
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026 - PR Newswire
Earnings call transcript: Viking Therapeutics Q1 2026 sees widened net loss - Investing.com India
Earnings call transcript: Viking Therapeutics Q1 2026 sees widened net loss By Investing.com - Investing.com South Africa
Viking Therapeutics Inc Azioni (VKTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Viking Therapeutics Inc Azioni (VKTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
Jan 05 '26 |
Sale |
32.90 |
57,661 |
1,896,969 |
189,891 |
| Mancini Marianna | Chief Operating Officer |
Jan 05 '26 |
Sale |
32.98 |
57,661 |
1,901,405 |
409,190 |
| Lian Brian | President & CEO |
Jan 05 '26 |
Sale |
32.96 |
233,409 |
7,692,121 |
2,499,291 |
| FOEHR MATTHEW W | Director |
Jan 02 '26 |
Option Exercise |
3.33 |
16,000 |
53,280 |
148,036 |
| FOEHR MATTHEW W | Director |
Jan 02 '26 |
Sale |
35.11 |
16,000 |
561,694 |
132,036 |
2.25%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):